Tech Company Financing Transactions

Aeovian Pharmaceuticals Funding Round

Aeovian Pharmaceuticals closed a $37 million Series A funding round on 10/4/2019. Backers included Sofinnova Ventures, venBio and Apollo Ventures.

Transaction Overview

Company Name
Aeovian Pharmaceuticals
Announced On
10/4/2019
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Series A
Investors

Sofinnova Ventures (Lead Investor) (Sarah Bhagat)

venBio (Lead Investor) (Richard Gaster)

Apollo Ventures

Evotec

Proceeds Purpose
The proceeds from this financing will be used to advance its lead selective mTORC1 inhibitor, AE116, from the preclinical stage through clinical proof of concept for an undisclosed rare disease of the central nervous system (CNS).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
www.aeovian.com
Email Address
Not Recorded
Overview
We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases.
Profile
Aeovian Pharmaceuticals LinkedIn Company Profile
Social Media
Aeovian Pharmaceuticals Company Twitter Account
Company News
Aeovian Pharmaceuticals News
Facebook
Aeovian Pharmaceuticals on Facebook
YouTube
Aeovian Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Stelios Tzannis
  Stelios Tzannis LinkedIn Profile  Stelios Tzannis Twitter Account  Stelios Tzannis News  Stelios Tzannis on Facebook
Chief Financial Officer
Benjamin Zadik
  Benjamin Zadik LinkedIn Profile  Benjamin Zadik Twitter Account  Benjamin Zadik News  Benjamin Zadik on Facebook
VP - Regulatory Affairs
Curtis Scribner
  Curtis Scribner LinkedIn Profile  Curtis Scribner Twitter Account  Curtis Scribner News  Curtis Scribner on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/4/2019: Tenaya Therapeutics venture capital transaction
Next: 10/4/2019: Mon Ami venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.